Frontline immunotherapy for NSCLC — the tale of the tail

The CHECKMATE-227 trial of nivolumab and ipilimumab presents a potential new frontline chemotherapy-sparing treatment option for patients with PD-L1-positive non-small-cell lung cancer and perhaps, in the future, also for those with PD-L1-negative disease. Indeed, the true predictive value of PD-L1...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Clinical oncology 2020-02, Vol.17 (2), p.73-74
Main Authors: Chiang, Anne C., Herbst, Roy S.
Format: Article
Language:English
Subjects:
631/67/1857
692/4028/67/580
692/699/67/1059/2325
692/699/67/1612/1350
692/700/565/251
Apoptosis
Cancer
Carboplatin
Carcinoma, Non-Small-Cell Lung
Care and treatment
Chemotherapy
Humans
Immunotherapy
Ipilimumab
Lung cancer
Lung cancer, Non-small cell
Lung Neoplasms
Medical colleges
Medicine
Medicine & Public Health
Monoclonal antibodies
News & Views
news-and-views
Nivolumab
Non-small cell lung carcinoma
Oncology
PD-L1 protein
Pharmaceutical industry
Small cell lung carcinoma
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The CHECKMATE-227 trial of nivolumab and ipilimumab presents a potential new frontline chemotherapy-sparing treatment option for patients with PD-L1-positive non-small-cell lung cancer and perhaps, in the future, also for those with PD-L1-negative disease. Indeed, the true predictive value of PD-L1 as well as tumour mutational burden remains to be determined, as neither biomarker segregates clearly with responsiveness.
ISSN:1759-4774
1759-4782
DOI:10.1038/s41571-019-0317-y